This article presents an overview of the 5 Hot Penny Stock On the Move. For a detailed overview of such stocks, read our article, 15 Hot Penny Stock On the Move.
5. Ocugen Inc (NASDAQ:OCGN)
Stock Performance Over the Past One Month: +87%
Clinical stage biopharma company Ocugen Inc (NASDAQ:OCGN) shares have gained about 87% over the past one month.
In November Ocugen Inc (NASDAQ:OCGN) posted third quarter results. Third quarter EPS came in at -$0.06, beating estimates by $0.01.
4. Applied Therapeutics Inc (NASDAQ:APLT)
Stock Performance Over the Past Five Days Through February 22: +79%
Applied Therapeutics Inc (NASDAQ:APLT) shares jumped about 79% over the past five days through February 22. These gains came after Applied Therapeutics Inc (NASDAQ:APLT) said its Phase 3 INSPIRE trial for lead candidate govorestat (AT-007) reached main goals against a rare neurological condition known as Sorbitol Dehydrogenase (SORD) Deficiency.
As of the end of the third quarter of 2023, 15 hedge funds out of the 910 funds tracked by Insider Monkey had stakes in Applied Therapeutics Inc (NASDAQ:APLT).
3. Sangamo Therapeutics Inc (NASDAQ:SGMO)
Stock Performance Over the Past Five Days Through February 22: +48%
Sangamo Therapeutics Inc (NASDAQ:SGMO) shares are gaining after Sangamo Therapeutics Inc (NASDAQ:SGMO) announced regulatory updates for its gene therapy candidate ST-920 in the treatment of Fabry disease and said it was actively seeking a collaboration partner for the product.
2. Renalytix PLC (NASDAQ:RNLX)
Stock Performance Over the Past One Month: 135%
Renalytix PLC (NASDAQ:RNLX) shares jumped by as much as 500% after Renalytix PLC (NASDAQ:RNLX) said the Centers for Medicare & Medicaid Services (CMS) has released a draft local coverage determination for KidneyIntelX and KidneyIntelX.dkd, marking a significant milestone for Renalytix PLC (NASDAQ:RNLX).
If the draft is approved, it will establish coverage for its diagnostic platform, KidneyIntelX, and its testing service, KidneyIntelX.dkd.
1. Monopar Therapeutics Inc (NASDAQ:MNPR)
Stock Performance Over the Past Five Days Through February 22: +191%
Monopar Therapeutics Inc (NASDAQ:MNPR) said the company has received Human Research Ethics Committee (HREC) clearance in Australia to commence a Phase 1 dosimetry trial of its novel radiopharmaceutical MNPR-101-Zr.
The company has reported positive preclinical data for its MNPR-101 program. The drug candidate targets cancers expressing the urokinase plasminogen activator receptor, or uPAR, which includes a majority of triple-negative breast, colorectal and pancreatic cancers, according to the company.
Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below. You can also look at the 13 Hot Penny Stocks To Buy According to Hedge Funds and the 10 Best Debt Free Penny Stocks To Buy Now.
